ClinicalTrials.gg
CompletedNCT05848011Updated May 22, 2026

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 interventional study of lorigerlimab and docetaxel in Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms and Prostate Cancer Recurrent, sponsored by MacroGenics. Completed at 61 sites in 10 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by MacroGenics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 17 open to participants now, 23 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.

Enrollment
14th of 42
154 · median 91
Started
2023
with 5 others
Phase 2
9 of 50
1 open now
Registered
33rd of 50
by date
Lead sponsor
4 of 50
MacroGenics

Among the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is the 14th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2023, is one of 9 in phase 2, and was the 33rd registered.

Prostatic Neoplasms, Castration-Resistant

85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

17 of the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who receive lorigerlimab in addition to the standard of care (SOC) of docetaxel and prednisone. About 150 participants with mCRPC will be enrolled. Participants will be randomized in a 2:1 ratio to receive lorigerlimab with docetaxel and prednisone (experimental arm) or docetaxel and prednisone alone (standard-of-care arm).

Lorigerlimab+docetaxel or docetaxel will be administered intravenously (IV) in clinic on Day 1 of each 3-week cycle. Prednisone will be administered orally twice daily. Lorigerlimab will be administered for up to 35 cycles. Docetaxel and prednisone will be administered up to 10 cycles until treatment discontinuation criteria are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI) and prostate-specific antigen (PSA) blood tests. Participants will be asked to complete questionnaires about their health and well-being. Routine examinations and blood tests will be performed and evaluated by the study doctor.

Participants who have disease progression standard-of-care arm have the option of continuing on the study to receive lorigerlimab monotherapy.

03

Conditions studied

  • Androgen-Independent Prostatic Cancer
  • Androgen-Independent Prostatic Neoplasms
  • Prostate Cancer Recurrent
  • Androgen-Insensitive Prostatic Cance
  • Androgen-Resistant Prostatic Cancer
  • Hormone Refractory Prostatic Cancer
  • Immunotherapy
  • Immune Checkpoint Inhibitor
  • Inhibitory Checkpoint Molecule
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • castration-resistant adenocarcinoma of the prostate without evidence of neuroendocrine differentiation, signet cell, or small cell features.
  • Participants must have ≥ 1 metastatic (measurable or non-measurable per PCWG3) lesion.
  • Participant has prostate cancer progression at study entry based on PCWG3 criteria.
  • Participant shows evidence of disease progression after receiving at least 1 prior androgen receptor axis-targeted therapy (ARAT) regimen (e.g., abiraterone, enzalutamide, apalutamide, or darolutamide).
  • Patients with known history of documented breast cancer gene (BRCA) mutation (germline or somatic) must have received an approved poly ADP ribose polymerase (PARP) inhibitor regimen.
  • Participants must have adequate performance status, and laboratory values.

Exclusion criteria

Exclusion Criteria:

  • Any condition preventing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
  • Received prior chemotherapy for mCRPC or for prostate cancer.
  • Current active or chronic infections.
  • Any heart, lung, or gastrointestinal disorders.
  • Allergy to any of the study treatments or components of the study treatments.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Lorigerlimab + Docetaxel and Prednisone

    Lorigerlimab 6 mg/kg IV (up to 2 years) and docetaxel 75 mg/m\^2 IV every 3 weeks (up to 7 months) and prednisone 5 mg orally twice daily (up to 7 months).

    Biological: lorigerlimab · Drug: docetaxel · Drug: Prednisone

  • Other
    Standard of care docetaxel and prednisone

    Docetaxel 75 mg/m\^2 IV every 3 weeks and prednisone 5 mg orally twice daily.(up to 7 months)

    Drug: docetaxel · Drug: Prednisone

Interventions

  • Biologicallorigerlimab

    Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4

    Also known as: MGD019

  • Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer

    Also known as: Taxotere®

  • A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer

06

What researchers measure

Primary outcomes

  1. Median radiographic progression free survival (rPFS) determined by investigator review.

    The rPFS is defined as the time from the date of randomization to the date of first documented PD per Prostate Cancer Working Group 3 (PCWG3) criteria or death from any cause, whichever occurs first.

    Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years

Secondary outcomes

  1. Objective response rate (ORR) per PCWG3 criteria

    ORR is defined as the number of participants who have a best overall response of confirmed complete response (CR) or partial response (PR) without prior confirmed bone progression

    Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years

  2. Duration of response (DoR)

    DoR is the time from the date of initial tumor response (CR or PR) to the date of first disease progression or death from any cause, whichever occurs first.

    Time frame: Every 9 weeks for the first year, then every 12 weeks for up to 4 years

  3. Time to response (TTR)

    TTR is defined as the time from the start of treatment to the first objective response (CR or PR).

    Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years

  4. PSA50 response rate

    PSA50 response is defined as a ≥ 50% decline in PSA from baseline with confirmation at least 3 weeks after the first documented reduction in PSA of ≥ 50%.

    Time frame: Every 3 weeks up to 2 years, followed by every 12 weeks for up to 2 more years

  5. PSA90 response rate

    PSA90 response is defined as a ≥ 90% decline in PSA from baseline with confirmation at least 3 weeks after the first documented reduction in PSA of ≥ 90%.

    Time frame: Every 3 weeks up to 2 years, followed by every 12 weeks for up to 2 more years

  6. Time to PSA progression

    Time to PSA progression is defined as the time from the date of randomization to the first documented PSA progression.

    Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 2 more years

  7. Duration of PSA response

    Duration of PSA response is defined as the time from the date of first PSA response to the earliest date of PSA progression.

    Time frame: Every 3 weeks up to 2 years, followed by every 23 weeks for up to 2 more years.

  8. Overall survival (OS)

    OS is defined as the time from the date of randomization to the date of death from any cause.

    Time frame: Throughout the study up to 4 years

  9. Time to First Symptomatic Skeletal Event (SSE)

    Time to first SSE is defined as the time from the date of randomization to the first occurrence of SSE from any cause.

    Time frame: Throughout the study up to 4 years

  10. Time to pain progression using the BPI-sf questionnaire

    Time to pain progression is defined as the time interval from randomization to the first date a participant experiences pain progression. Higher scores indicate more severe pain.

    Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 2 more years

  11. Pain severity using the Brief Pain Index - short form (BPI-sf) questionnaire

    The BPI-sf pain severity score consists of 4 items that assess pain at its worst, least, average, and current pain intensity. The pain severity score is the average of the 4 item scores. Higher scores indicate more severe pain.

    Time frame: Every 3 weeks up to 2 years

  12. Pain interference using the BPI-sf questionnaire

    The BPI-sf pain interference score includes 7 items: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The pain interference score is the average of the 7 interference items. Higher scores indicate more interference from pain in daily life.

    Time frame: Every 3 weeks up to 2 years

  13. Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire

    The FACT-P consists of 27 items from the Functional Assessment of Cancer Therapy-General (FACT-G) that measure physical, social/family, emotional, and functional well-being and 12 items that compose the Prostate Cancer Subscale (PCS). Higher scores indicate greater impact of prostate cancer on daily life.

    Time frame: Every 3 weeks up to 2 years

  14. Description of types of adverse events (AEs) between treatment groups.

    Number of participants with adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation

    Time frame: Throughout treatment up to 27 months

  15. Lorigerlimab maximum concentration or concentration at the end of infusion (Cmax)

    The highest measured concentration of lorigerlimab in the bloodstream.

    Time frame: Every 21-day cycle throughout the study, for an average of 1 year.

  16. Lorigerlimab area under the concentration time curve (AUC)

    AUC is the total amount of lorigerlimab in bloodstream after drug administration

    Time frame: Every 21-day cycle throughout the study, for an average of 1 year.

  17. Trough drug concentration (Ctrough or Cmin)

    Trough concentration is the concentration measured before a subsequent dose of lorigerlimab

    Time frame: Every 21-day cycle throughout the study, for an average of 1 year.

  18. Clearance (CL)

    Drug clearance is the amount of drug removed from the bloodstream by the body per unit of time

    Time frame: Every 21-day cycle throughout the study, for an average of 1 year.

  19. Volume of distribution (Vz)

    The volume of distribution is related to how much drug is distributed to body tissues, or remains in the bloodstream.

    Time frame: Every 21-day cycle throughout the study, for an average of 1 year.

  20. Terminal half-life

    Terminal elimination half-life is the time it takes for the concentration of the drug in plasma or serum to be reduced by 50%

    Time frame: Every 21-day cycle throughout the study, for an average of 1 year.

  21. Number of participants who develop anti-drug antibodies

    Time frame: Throughout the study, up to 2 years

07

Study locations

61 sites
  • United Medical Group
    Miami, Florida 33135, United States
  • Orlando Health Cancer Institute
    Orlando, Florida 32806, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Nebraska Cancer Specialists
    Grand Island, Nebraska 68803, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • START Mountain Region
    West Valley City, Utah 84119, United States
  • University of Virginia Health System Cancer Center
    Charlottesville, Virginia 22903, United States
  • Concord Repatriation General Hospital
    Concord, Australia
  • Peter MacCallum Cancer Centre
    North Melbourne, Australia
  • North Shore Private Hospital
    St Leonards, Australia
  • Westmead Hospital
    Westmead, Australia
  • Cliniques universitaires Saint-Luc (CUSL), Brussels
    Brussels, Belgium
  • UZ GENT
    Ghent, Belgium
  • Centre Hospital de l'Ardenne
    Libramont, Belgium
  • CHU de Liège
    Liège, Belgium
  • MHAT Dr. Tota Venkova
    Gabrovo, Bulgaria
  • Comprehensive Cancer Center
    Plovdiv, Bulgaria
  • UMHAT Sv. Ivan Rilski
    Sofia, Bulgaria
  • Institut Bergonie
    Bordeaux, France
  • Clinique Victor Hugo
    Le Mans, France
  • Centre Léon Bérard
    Lyon, France
  • Centre Antoine Lacassagne
    Nice, France
  • Institut Mutualiste Montsouris
    Paris, France
  • Centre Hospitalier Quimper
    Quimper, France
  • CHP Saint Grégoire
    Saint-Grégoire, France
  • Hia Begin
    Saint-Mandé, France
  • Hopital Foch
    Suresnes, France
  • Institut Gustave Roussy
    Villejuif, France
  • LTD High Tech Hosp Medcenter
    Batumi, Georgia
  • First University Clinic TSMU
    Tbilisi, Georgia
  • LTD Consilium Medulla
    Tbilisi, Georgia
  • Ltd Gidmedi
    Tbilisi, Georgia
  • LtD L.M.National Urology Center
    Tbilisi, Georgia
  • LTD MMT Hospital
    Tbilisi, Georgia
  • LTD Todua Clinic
    Tbilisi, Georgia
  • Onc. Scient. Research Center
    Tbilisi, Georgia
  • Przychodnia Lekarska KOMED
    Konin, Poland
  • Szpital Woj. im M Kopernika
    Koszalin, Poland
  • Pratia McM Kraków
    Krakow, Poland
  • Europejskie Centrum Zdrowia Otwock, Szpital im. Fryderyka Chopina
    Otwock, Poland
  • LuxMed Onkologia
    Warsaw, Poland
  • Medical Concierge
    Warsaw, Poland
  • Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o., Oddział Chemioterapii
    Warsaw, Poland
  • Pan American Center for Oncology Trials, LLC
    Rio Piedras, Puerto Rico
  • H U Germans Tries i Pujol
    Barcelona, Spain
  • Hospital Clínic de Barcelona
    Barcelona, Spain
  • Hospital del Mar
    Barcelona, Spain
  • Hospital Parc Tauli
    Barcelona, Spain
  • Hospital Sant Pau
    Barcelona, Spain
  • Institut Català d'Oncologia Hospitalet_ICO Hospitalet
    Barcelona, Spain
  • Vall d' Hebron Institute of Oncology (VHIO)
    Barcelona, Spain
  • Hospital 12 de octubre
    Madrid, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, Spain
  • FIVO: Instituto Valenciano de Oncología
    Valencia, Spain
  • Churchill Hospital
    Headington, United Kingdom
  • Charing Cross Hospital
    London, United Kingdom
  • Royal Marsden Hospital
    Sutton, United Kingdom
  • Musgrove Park Hospital
    Taunton, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Feb 2026, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2023
First posted
May 8, 2023
StartActual
Sep 28, 2023
Primary completionActual
Feb 19, 2026
CompletionActual
Mar 16, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05848011
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
May 8, 2023
Start date
Sep 28, 2023
Primary completion
Feb 19, 2026
Completion
Mar 16, 2026
Last update
May 22, 2026

Study contacts

Pepi Pencheva, M.D.
study director · MacroGenics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorigerlimab

Start the discussion